The pharmaceutical firm's WuXi Healthcare Ventures unit contributed to a series A round that will support CStone's drug candidates advance through clinical trials.
China-based biopharmaceutical startup CStone Pharmaceuticals closed a $150m series A round yesterday featuring WuXi Healthcare Ventures, the strategic investment arm of pharmaceutical research company WuXi PharmaTech.
The round also included Oriza Seed Venture Capital, the investment platform located in Suzhou Industrial Park and operated by the park’s Suzhou Oriza Holdings unit, as well as investment firm Boyu Capital.
CStone is developing therapeutics from a product pipeline covering five areas – oncology, cardiovascular diseases, rheumatoid arthritis, haematology and autoimmune diseases –…